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ABSTRACT 
Polymers have become an integral part of drug delivery systems due to their improved pharmacokinetics properties. Polymer conjugation is a 
well-known and widely exploited technique useful to improve therapeutic properties of peptides, proteins, small molecules and 
oligonucleotides. Polymer conjugated drug generally exhibit prolonged half-life, higher stability, water solubility, lower immunogenicity, 
antigenicity and often also to the specific targeting tissue. Polymer materials are designed to be capable of delivering active substance. to the 
target diseased tissues and  cells. Conjugation of Ibuprofen and polyethylene glycol (PEG) helps to increase the duration of action of the parent 
drug. The PEG-Ibu conjugates were synthesized from ibuprofen and PEG with two different molecular weights by esterification in the presence 
of DCC and DMAP. The PEG-Ibu conjugation characterized by FT-IR, UV, DSC and NMR and also in-vitro drug release study in different buffer at 
different ph. 
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Improving the therapeutic index of drugs is a major impetus 
for innovation in many therapeutic areas such as cancer, 
inflammatory and infective diseases. In drug–polymer 
conjugates, however, the drug is covalently linked to 
polymers such as proteins, polysaccharides and synthetic 
polymers and also used a spacer molecule.  
Prof. H. Ringsdorf developed a rational model (Figure 1) of 
polymeric prodrug for the first time in 1975. And Prof. 
Ringsdorf was the first scientist to recognize the huge 
potential of polymeric prodrug, allowing polymer chemist 
and biologists would work together in the field. The 
proposed model consists mainly of fie components: the 
polymeric backbone, the drug, the spacer, the targeting 
group and the soluble agent. The backbone could be either 
an inert or a biodegradable polymer. The role of spacer is to 
control the site and the rate of releasing the active drug from 
the conjugate by hydrolytic or enzymatic cleavage. The drug 
must be covalently bonded and must remain attached to the 
polymer until this macromolecule reaches the target site. So, 
the drug chosen must be potent and intact until it reaches 
the target. Besides, it should have a functional group to bind 
with the polymer backbone directly. The targeting moiety or 
homing device guides the entire polymer-drug conjugate to 
the targeted tissue. Now, in general, there are different kinds 
of the therapeutic agents could be incorporated into polymer 




Figure 1: Prof. H. Ringsdorf model 
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Conjugation of ibuprofen to polyethylene glycol (PEG) 
Non-steroidal anti-inflammatory drugs (NSAIDs) are usually 
poorly soluble in water and they frequently cause 
gastrointestinal side effects such as gastric ulceration, 
bleeding and perforation. Ibuprofen is a non-steroidal anti-
inflammatory drug with well-known anti-inflammatory, 
antipyretic and analgesic properties. Chemically it is 2-(4-
iso-butylphenyl)- propanoic acid and is poorly soluble in 
water . It is most commonly administered orally and is 
rapidly absorbed to reach its maximal plasma concentration 
with in 2 hrs. However, it has a short biological half-life of 2 
hrs, which means that frequent doses are required to 




Poly (ethylene glycol) 600(PEG) was obtained from M/s. 
Merck. Mumbai. Thionyl chloride, and glycine were obtained 
from M/s. SD Fine Chemicals and used as such.  Glycine  was 
obtained from M/s. Loba Chemicals, Mumbai, and used as 
such.  Dicyclohexyl carbidomide (DCC) and 4-dimethyl 
amino pyridine (DMAP) were obtained from M/s. Merck, 
Germany. Triethylamine, Dimethylformamide (DMF) were 
obtained from M/s. Ranbaxy fine Chemicals. Ibuptofen was 
obtained from M/s. Matrix Laboratories Limited, and was 
used after confirming its purity by its melting point and IR 
spectrum. All other solvents used were purified by standard 
techniques . 
I. Preparation of Chloro derivative of PEG  (PEG-cl2)   
Poly(ethylene glycol)600 (10mmol) and pyridine (20mmol) 
were taken in a 250 ml two-necked round bottom flask fitted 
with a stirrer and condenser. Thionylchloride (60mmol) was 
added drop by drop for 30 minutes under reflux maintaining 
the temperature at 400C. When the addition was complete, 
the temperature of the flask was raised to 700C and the 
reaction was carried out for 5h. The temperature was then 
brought to room temperature and the contents were filtered 
to remove pyridine hydrochloride. The residue was 
dissolved in methylene chloride, dried over anhydrous 
potassium carbonate and filtered. The filtrate was treated 
with alumina (50g, activated at 1200C for 1h), precipitated 
by cold diethyl ether and crystallized from ethanol.  
Chloro derivative of poly-(ethylene glycol) (PEG-cl2) 
obtained was characterized by single spot thin layer 
chromatography and spectral analysis. The IR spectrum was 
recorded in KBr pellet using Perkin-Elmer 1600 series FTIR 
spectrophotometer.   
II. Covalent binding of Glycine to PEG – Cl2  
To a solution of PEG-Cl2 (6mmol) and pyridine (6mmol) in 
DMF (20ml), glycine (30mmol) was added in small portions 
for 3h under stirring at room temperature. The mixture was 
then refluxed at 1300C for 8h with continuous stirring. The 
solvent was removed under reduced pressure and the 
residue was dissolved in dichloromethane. The solution was 
cooled, filtered and diethyl ether was added. The PEG-
(Glycine-COOH)2 precipitated was recrystallised from 
ethanol and purified by column chromatography using 
methanol and water in the ratio of 3:1. The PEG-(Glycine-
COOH)2 was characterized by single spot TLC and spectral 
analysis. The IR spectrum was recorded in nujol using 
Perkin -Elmer 1600 series, FTIR spectrophotometer. The H1 
and C13 NMR spectra were recorded using JEOL 
spectrometer. Similar procedures were adopted for the 
coupling of leucine  with PEG-Cl2 to obtain PEG-(Leucine-
COOH)2 .  
III. Synthesis of PEG-[(Glycine)-Ibuprofen] 
A solution of DCC (15mmol), DMAP (6mmol) in 10ml of DMF 
was taken in a 250ml beaker. The solution was then added 
drop by drop to another 250ml beaker containing a solution 
of PEG-(glycine-COOH)2 (6mmol) dissolved in DMF (20ml). 
Ibuprofen (15mmol) was added in small portions to this 
mixture, maintained at 00C for 10 minutes. The coupling 
reaction was carried out for 4 days (96h) at room 
temperature with continuous stirring. At the end of the 
fourth day, the solvent was removed under reduced 
pressure and the residue was dissolved in dichloromethane 
and washed with brine. The organic layer was separated and 
dried over anhydrous potassium carbonate. The organic 
layer was concentrated and diethyl ether was added. The 
precipitated product, namely PEG-[(glycine)-Ibuprofen] , was 
recrystallised twice from dichloromethane and was further 
purified by column chromatography using methanol and 
water in the ratio of 3:1 The PEG - [(glycine)-Ibuprofen] was 
characterized by single spot TLC and spectral analysis. The 
IR spectrum was recorded in nujol using perkin-Elmer 1600 
series FT IR spectrophotometer. The H1 and C13 NMR 
spectrum were recorded in JEOL Spectrometer. 
Evaluation Studies 
Estimation of Drug content  
A stock solution of ibuprofen will be prepare by dissolving 
100 mg of the drug in 100 ml of 0.1N NaOH. From the stock 
solution 10, 20, 30, 40 and    50 μg/ml dilutions is being 
prepare using phosphate buffer of pH 7.4. The λmax of the 
drug will determine by scanning the diluted solution 
between 200-400nm against a blank reagent in a double 
beam spectrophotometer (model UV 160 A).  
In vitro Drug Release Studies  
In vitro drug release testing will, therefore, carry out to 
assess the potential of the PEG drug conjugates synthesized. 
The in vitro drug release from the polymeric pro-drug will 
evaluated using USP XXIII dissolution apparatus (type II, 
paddle). 
Studies in Different Buffers :100mg each of the pro-drug 
containing a known quantity of the drug will be taken in 
900ml dissolution media of pH 1.2 (HCl buffer), 5.5 
(Phthalate buffer), 6.8 (Phosphate buffer) and pH 7.4 
(Phosphate buffer). It is stirred at 100 rpm over a period of 
24h. Samples (5ml) are withdrawn at time intervals of 0.5, 1, 
1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h. After each sample 
withdrawn, an equal quantity of fresh dissolution mediais 
replaced. The absorbance of the samples withdrawn after 
suitable dilution, will measured against the blank at the λmax 
of the drug, namely, 254 nm. The amount of the drug 
released at different time intervals and percentage release 
was calculated using the formula, ‘ 
           
                                    
             
      
Stability studies 
Accelerated stability studies for the synthesized PEG 
conjugates will carry out for three months. The pro-drugs 
containing equivalents of 100 mg of the parent drug (3 
batches each)  fills manually in hard gelatin capsules (size 1) 
and then packed in transparent polyvinyl chloride blisters of 
0.25 mm thickness. Three different temperature and 
humidity conditions, prescribed by the International 
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Conference on Harmonization (ICH) for zone IV, were 
employed namely, 
 25oC with 60% relative humidity (RH). 
 40oC with 75% relative humidity (RH). 
 Room temperature. 
Samples were withdrawn at the end of 30, 60 and 90 days 
and evaluated for their physical parameters and in vitro drug 
release. The drug content in each batch will evaluate. 
RESULT AND DISCUSSION 
Synthesis of polymeric pro-drugs 
a) Synthesis of the Chloro derivative of PEG (PEG-Cl2) 
The synthesis of chloro derivative of PEG is given in Scheme 
1.  
 
Scheme 1: Synthesis of the Chloro derivative of PEG 
 
 
Figure 2: IR OF PEG-Cl2 
PEG-Cl2 was obtained in good yield (yield 83%, mp. 41° C). The IR spectrum for PEG and . PEG exhibits a characteristic bands at 
3375 cm-1 (OH), 2878 cm-1  (-CH2) and at 1086cm-1 (– CH2 – O – CH2 stretching). PEG-Cl2 exhibits bands at 1179cm-1 (–CH2–O–
CH2 stretching), 753cm-1 (–C–Cl stretching), 2898cm-1 (-CH2-) and no absorption for -OH at 3300 – 3500 cm-1, indicating the 
replacement of -OH by -Cl.  
 
Figure 3: IR OF PEG600 
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b)  Covalent binding of Glycine to PEG – Cl2 
The coupling of PEG-Cl2 to glycine is given in Scheme 2.  
 
Scheme 2: Covalent binding of Glycine to PEG – Cl2 
  
FTIR of PEGCl2-Glycine 
 
 
Figure 4: FTIR of PEGCl2-Glycine 
PEG – (glycine - COOH) 2 was obtained in good yield (yield 80%, mp. 62° C).   
IR (nujol) spectrum shows a broad band between 2500-3400cm-1 (-COOH, NH), 1651cm-1 (C=O) and 1064cm-1 (-C-O-C). 
C) PEG – Cl2 –Glycine to Ibuprofen 
 
 
             + 
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Figure 5: FTIR of Ibuprofen 
IR of Ibuprofen sprectum shows broad band between 2800-2953 cm-1 (CH), 1400-1706 cm-1 (C=C) . 
Estimation of Drug content         
The amount of drug present in each of the pro-drugs was estimated spectrophotometerically and is given in Table 1. It was 
found that as the spacer length increases, the amount of drug incorporated into the polymer backbone decreases. 
Table 1: Amount of drug present in each of the pro-drugs 
SNo PEG pro-drugs Drug content/100mg of pro-drug 
1 PEG [(Glycine) – Ibuprofen] 62.87mg 
 
Table 1: Estimated drug content of PEG - pro – drugs In-vitro drug release from [(GLYCINE) – Ibuprofen] at different pH 
time pH 1.2 pH 5.5 pH 6.8 pH 7.4 
0 0 0 0 0 
0.5 2.02 3.89 4.01 5.63 
1 5.68 8.62 9.23 10.62 
1.5 6.48 16.59 17.18 18.51 
2 7.56 19.82 20.34 22.63 
3 8.98 28.93 29.14 30.62 
4 11.23 32.12 35.34 40.81 
6 13.68 39.62 42.18 46.23 
8 14.92 42.83 45.34 52.16 
10 15.23 48.23 50.12 58.83 
12 17.18 50.34 55.18 60.24 
18 20.34 53.18 60.24 64.97 
24 22.14 56.24 62.18 66.28 
 
 





















pH1.2 pH 5.5 pH6.8 pH 7.4
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The in vitro release of acyclovir from the pro-drugs were 
evaluated in pH 1.2  (acidic buffer), pH 5.5(phathalate buffer) 
pH 6.8 and 7.4 (phosphate buffer).The in vitro drug release 
profiles of the pro-drugs, PEG-[(Glycine) – Ibuprofen]. 
The in vitro release profile of ibuprofen from the polymeric 
pro-drug (PEG-[(Glycine) – Ibuprofen] is given in Table and 
Figure. The data shows that the release of ibuprofen is 
sustained over a period of 24h. At pH 7.4 a maximum of 
66.28% was released and the time taken for 50% of drug 
release (T50) was 8h. At pH 6.8, a maximum of 62.18% was 
released with a T50 of 10h. At pH 5.5 a maximum of 56.24% 
was released with a T50 of 12h. Eventhough the drug release 
was sustained at pH 1.2, the amount of drug released over a 
period of 24h was much lower (22.14%) when compared to 
the higher Ph. 
Stability Studies 
Duration (in days) PEG Cl2-Glycine (Ibuprofen) 
 
At 25 oC / 60% RH 
          0 60.78 
         30 67.58 
         60 58.50 
         90 62.50 
 













Main objective of PEG-Ibu conjugation to improve the 
duration of action. The biologically active drug and a polymer 
conjugation is one of the numerous methods for changing 
and controlling the pharmacokinetics, biodistribution, and 
also helps to decrease the toxicity of the compound. 
Conjugation of PEG with ibuprofen also helps the control 
release of drug from the system. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are usually 
poorly soluble in water and they frequently caused 
gastrointestinal side effects such as gastric ulceration, 
bleeding and perforation, Ibuprofen is a NSAIDs with well 
known anti inflammatory, antipyretic and analgesic 
properties. Chemically it is 2-(4-iso butylphenyl)propanoic 
acid poorly soluble in water. It is mostly administered orally; 
it has a short biological half life of 2 hrs which means 
frequent doses are required to maintain the therapeutic 
efficacy over extended time periods. These problems can be 
overcome by preparation of polymeric prodrug which helps 
to the decrease the dose and also reduced toxicity. 
In this study PEG is being used as the carrier polymer , 
because it is known to as nontoxic , non-antigenic and non 
teratogenic , non-immunogenic ,biocompatible ,available in 
variety of molecular weights, linear, uncharged, amiphilic 
polymer, widely soluble in water and in most organic 
solvents and has solubilizing properties.  
CONCLUSION 
This article deals with the investigations carried out by the 
writer on the synthesis, characterization and evaluation of 
some polymeric pro-drugs. This technique of polymeric 
prodrug conjugation is a fascinating approach for efficient 
drug delivery and appears to have a bright future in 
therapeutics. PEG-Ibu conjugation helps to increase the 
therapeutic activities , it helps to reduce the dose no which 
leads to reduce toxicity. Main objective of this experiment is 
that to control the release of drug and improve the duration 
of action.  
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